Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLV026
MIFTS: 56

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Salivary Gland Carcinoma

About this section

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 37 55 43 15
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Malignant Neoplasm of Salivary Gland 12
Salivary Gland Neoplasm 29

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
ICD10 33 C08
ICD9CM 35 142.8
KEGG 37 H01508
UMLS 73 C0153362
Sources

Summaries for Salivary Gland Carcinoma

About this section
MedlinePlus : 43 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and salivary gland cancer, adult. An important gene associated with Salivary Gland Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and Phospholipase-C Pathway. The drugs Iodine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Sources

Related Diseases for Salivary Gland Carcinoma

About this section

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 31.4 AREG CRTC1 CRTC3 EGFR MAML2
2 salivary gland cancer, adult 12.6
3 salivary gland cancer, childhood 12.3
4 adenoid cystic carcinoma 11.5
5 brooke-spiegler syndrome 11.2
6 sublingual gland cancer 11.2
7 parotid gland cancer 11.2
8 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
9 deafness, autosomal recessive 39 10.3 HGF MET
10 pharynx cancer 10.3 CDKN2A EGFR KIT
11 infiltrating angiolipoma 10.2 CDKN2A MDM2
12 deafness, autosomal recessive 97 10.2 HGF MET
13 anaplastic oligodendroglioma 10.2 CDKN2A EGFR
14 acral lentiginous melanoma 10.2 CDKN2A KIT MET
15 small cell carcinoma 10.2 CDKN2A EGFR KIT
16 chordoma 10.2 CDKN2A EGFR MET
17 fibrosarcoma of bone 10.2 CDKN2A KIT MDM2
18 doxorubicin induced cardiomyopathy 10.2 EGFR HGF MET
19 supratentorial cancer 10.2 CDKN2A EGFR MDM2
20 endometrial squamous cell carcinoma 10.2 CDKN2A HGF MET
21 familial renal papillary carcinoma 10.2 EGFR HGF MET
22 cerebrum cancer 10.2 CDKN2A EGFR MDM2
23 grade iii astrocytoma 10.2 CDKN2A EGFR MDM2
24 spinal chordoma 10.2 EGFR HGF MET
25 central nervous system melanocytic neoplasm 10.2 CDKN2A HGF KIT
26 sarcoma, synovial 10.2 KIT MDM2 MET
27 nervous system cancer 10.2 CDKN2A EGFR MDM2
28 lacrimal gland mucoepidermoid carcinoma 10.2 CRTC1 MAML2
29 li-fraumeni syndrome 10.2 CDKN2A EGFR MDM2
30 spindle cell synovial sarcoma 10.2 HGF ISL1 MET
31 cutaneous mucoepidermoid carcinoma 10.2 CRTC1 MAML2
32 conventional fibrosarcoma 10.2 KIT MDM2
33 malignant peripheral nerve sheath tumor 10.2 CDKN2A EGFR KIT MDM2
34 breast mucoepidermoid carcinoma 10.2 CRTC1 MAML2
35 large cell medulloblastoma 10.2 HGF MET
36 adenoid basal cell carcinoma 10.2 CDKN2A KIT
37 clear cell hidradenoma 10.1 CRTC1 MAML2
38 glioblastoma multiforme 10.1 CDKN2A EGFR MDM2 MET
39 connective tissue cancer 10.1 AREG KIT MDM2
40 melanoma, uveal 10.1 CDKN2A MDM2 MET
41 female reproductive system disease 10.1 AREG CDKN2A EGFR
42 reproductive system disease 10.1 AREG CDKN2A EGFR
43 stomach disease 10.1 AREG EGFR MET
44 atypical lipomatous tumor 10.1 CDKN2A MDM2
45 renal cell carcinoma, nonpapillary 10.1 EGFR HGF KIT MET
46 myoepithelioma 10.1
47 pleomorphic adenoma 10.1
48 cervical adenosquamous carcinoma 10.1 CDKN2A CRTC1 EGFR MAML2
49 necrotizing sialometaplasia 10.1 CDKN2A CRTC1 KIT MAML2
50 glioma 10.1 CDKN2A EGFR MDM2 MET

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma
Sources

Symptoms & Phenotypes for Salivary Gland Carcinoma

About this section

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 CDK9 EGFR
2 Decreased viability GR00221-A-1 10.3 CDK9 CDKN2A EGFR HGF CYLD KIT
3 Decreased viability GR00221-A-2 10.3 CDK9 HGF CYLD
4 Decreased viability GR00221-A-3 10.3 CDKN2A
5 Decreased viability GR00221-A-4 10.3 CDK9 CDKN2A EGFR HGF PNCK
6 Decreased viability GR00301-A 10.3 PNCK CYLD KIT
7 Decreased viability GR00402-S-2 10.3 CDK9 CDKN2A EGFR HGF PNCK CYLD
8 Decreased viability in Von Hippel-Lindau (VHL) (-/-) cell line GR00121-A 8.62 CDK9 MET

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 AREG CDK9 CDKN2A CRTC1 CRTC3 CYLD
2 homeostasis/metabolism MP:0005376 10.25 AREG CDKN2A CRTC1 CRTC3 CST5 CYLD
3 cardiovascular system MP:0005385 10.22 AREG CDK9 CDKN2A EGFR HGF ISL1
4 hematopoietic system MP:0005397 10.16 AREG CDKN2A CRTC1 CYLD EGFR HGF
5 endocrine/exocrine gland MP:0005379 10.15 AREG CDKN2A CRTC1 CYLD EGFR ISL1
6 digestive/alimentary MP:0005381 10.11 AREG CDKN2A CYLD EGFR ISL1 KIT
7 limbs/digits/tail MP:0005371 10.07 CRTC3 CST5 CYLD EGFR ISL1 KIT
8 integument MP:0010771 10.01 AREG CDK9 CDKN2A CYLD EGFR ISL1
9 liver/biliary system MP:0005370 9.87 CDKN2A CRTC3 EGFR HGF KIT MDM2
10 muscle MP:0005369 9.8 CDKN2A CRTC3 EGFR ISL1 KIT MDM2
11 neoplasm MP:0002006 9.7 CDKN2A CYLD EGFR ISL1 KIT MDM2
12 no phenotypic analysis MP:0003012 9.5 CDKN2A EGFR HGF ISL1 KIT MDM2
13 skeleton MP:0005390 9.28 CDKN2A CRTC3 CST5 EGFR ISL1 KIT
Sources

Drugs & Therapeutics for Salivary Gland Carcinoma

About this section

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
8
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
9
leucovorin Approved Phase 3,Phase 1 58-05-9 6006 143
10
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
12
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 cadexomer iodine Phase 3
18 Pharmaceutical Solutions Phase 3
19 Peripheral Nervous System Agents Phase 3,Phase 2
20 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
21 Autonomic Agents Phase 3,Phase 2
22 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
25 Dermatologic Agents Phase 3,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Not Applicable
27 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Early Phase 1
28 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
29 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
30 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Not Applicable
31 Antimetabolites Phase 3,Phase 1,Phase 2,Not Applicable
32 Cholinergic Agents Phase 3,Phase 2
33 Muscarinic Agonists Phase 3,Phase 2
34 Central Nervous System Depressants Phase 3
35 Adjuvants, Anesthesia Phase 3
36 Anesthetics, Intravenous Phase 3
37 Analgesics, Opioid Phase 3
38 Anesthetics, General Phase 3
39 Analgesics Phase 3,Phase 2
40 Narcotics Phase 3
41 Anesthetics Phase 3
42 Histamine Antagonists Phase 3
43 Psychotropic Drugs Phase 3
44 Antidepressive Agents Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46 Antidepressive Agents, Tricyclic Phase 3
47 Antirheumatic Agents Phase 3,Phase 2,Early Phase 1
48 Folic Acid Antagonists Phase 3,Phase 1
49 Vitamin B Complex Phase 3,Phase 2,Phase 1
50 Vitamin B9 Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 192)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
2 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
3 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
8 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
9 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
11 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
12 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
13 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
14 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
15 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Unknown status NCT02393820 Phase 2 pazopanib
16 Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck Unknown status NCT02558387 Phase 2 BIBF1120
17 Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers Unknown status NCT02867852 Phase 2 Abiraterone acetate
18 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
19 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
20 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
21 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
22 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
23 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
24 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
25 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed NCT01613768 Phase 2 eribulin mesylate
26 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
27 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
28 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
29 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
30 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
31 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
32 Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma Completed NCT00228488 Phase 2 Gefitinib
33 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
34 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
35 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed NCT01175980 Phase 2 Vorinostat
36 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
37 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
38 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
39 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
40 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
41 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
42 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
43 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
44 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
45 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
46 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
47 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
48 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
49 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
50 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride

Search NIH Clinical Center for Salivary Gland Carcinoma

Sources

Genetic Tests for Salivary Gland Carcinoma

About this section

Genetic tests related to Salivary Gland Carcinoma:

# Genetic test Affiliating Genes
1 Salivary Gland Neoplasm 29
Sources

Anatomical Context for Salivary Gland Carcinoma

About this section

MalaCards organs/tissues related to Salivary Gland Carcinoma:

41
Salivary Gland, Testes, Lymph Node, Lung, T Cells, Thyroid, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
The Salivary Gl
Sources

Publications for Salivary Gland Carcinoma

About this section

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 249)
# Title Authors Year
1
Impact of tumour profiling on clinical trials in salivary gland cancer. ( 30102009 )
2019
2
Development of a novel salivary gland cancer lymph node staging system. ( 29742277 )
2018
3
Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. ( 29949051 )
2018
4
AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. ( 29873033 )
2018
5
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. ( 29044862 )
2018
6
Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2A N0 high-grade salivary gland cancer. ( 29925355 )
2018
7
Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. ( 29555661 )
2018
8
Treatment Times in Salivary Gland Cancer: National Patterns and Association with Survival. ( 29460669 )
2018
9
Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: a multicenter retrospective analysis. ( 28936637 )
2018
10
Second primary cancer after major salivary gland carcinoma. ( 28960648 )
2018
11
Minor Salivary Gland Carcinoma of the Oropharynx: A Population-Based Analysis of 1426 Patients. ( 28971745 )
2018
12
Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma. ( 29151106 )
2018
13
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. ( 29211833 )
2018
14
Combined androgen blockade for salivary gland carcinoma. ( 29233558 )
2018
15
Retraction: Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes by Xu L, Tang H, Chen DW, El-Naggar AK, Wei P, Sturgis EM. ( 29406587 )
2018
16
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. ( 29462123 )
2018
17
Health-related quality of life in patients with major salivary gland carcinoma. ( 29478078 )
2018
18
Prognostic significance and optimal candidates of primary tumor resection in major salivary gland carcinoma patients with distant metastases at initial presentation: A population-based study. ( 29496064 )
2018
19
External beam radiotherapy for the treatment of feline salivary gland carcinoma: six new cases and a review of the literature. ( 29767566 )
2018
20
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. ( 29863801 )
2018
21
Retraction: Genetic Variants in DNA Double-Strand Break Repair Genes and Risk of Salivary Gland Carcinoma: A Case-Control Study. ( 29928030 )
2018
22
Salivary gland carcinoma: Prediction of cancer death risk based on apparent diffusion coefficient histogram profiles. ( 29975742 )
2018
23
Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. ( 30050326 )
2018
24
Pretreatment Primary Tumor and Nodal SUVmax Values on 18F-FDG PET/CT Images Predict Prognosis in Patients With Salivary Gland Carcinoma. ( 30273205 )
2018
25
Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. ( 30293119 )
2018
26
ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma. ( 30374620 )
2018
27
The limited role of elective neck dissection in patients with cN0 salivary gland carcinoma. ( 30528947 )
2018
28
Androgen deprivation therapy for metastatic salivary gland cancer. ( 30127038 )
2018
29
Insurance Status and Survival of Patients with Salivary Gland Cancer. ( 30324868 )
2018
30
Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats. ( 30338701 )
2018
31
Survival and characteristics of pediatric salivary gland cancer: A systematic review and meta-analysis. ( 30378272 )
2018
32
The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. ( 30472214 )
2018
33
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). ( 28102887 )
2017
34
Androgen Receptor Signaling in Salivary Gland Cancer. ( 28208703 )
2017
35
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. ( 28160551 )
2017
36
Effective nasal mask ventilation of a difficult airway in a patient with advanced salivary gland cancer. ( 28494881 )
2017
37
The rising incidence of major salivary gland cancer in the United States. ( 28346649 )
2017
38
Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. ( 28819427 )
2017
39
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
40
A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. ( 28133481 )
2017
41
Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. ( 28401485 )
2017
42
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2017
43
Immunohistochemical and molecular profile of salivary gland cancer in children. ( 28139061 )
2017
44
Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma. ( 27846763 )
2017
45
Complementary role of the Memorial Sloan Kettering Cancer Center nomogram to the American Joint Committee on Cancer system for the prediction of relapse of major salivary gland carcinoma after surgery. ( 28152230 )
2017
46
Retrospective study of 149 cases of salivary gland carcinoma in a Spanish hospital population. ( 28160579 )
2017
47
Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience. ( 28271999 )
2017
48
Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy. ( 28650891 )
2017
49
(A+)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ( 27670669 )
2016
50
Does age affect prognosis in salivary gland carcinoma patients? A national Danish study. ( 26825002 )
2016
Sources

Variations for Salivary Gland Carcinoma

About this section

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 376)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6845145 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 15
2 COSM6979379 TSHR salivary gland,major,carcinoma,NS c.1376C>T p.A459V 14:81143434-81143434 15
3 COSM6983845 TSC2 salivary gland,major,carcinoma,NS c.2276G>A p.R759K 16:2072904-2072904 15
4 COSM6939530 TSC2 salivary gland,major,carcinoma,NS c.2402C>T p.A801V 16:2074246-2074246 15
5 COSM6939527 TSC1 salivary gland,major,carcinoma,NS c.2684T>A p.V895D 9:132897552-132897552 15
6 COSM43878 TP53 salivary gland,major,carcinoma,NS c.427G>A p.V143M 17:7675185-7675185 15
7 COSM10662 TP53 salivary gland,major,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 15
8 COSM307275 TP53 salivary gland,major,carcinoma,NS c.96+1G>T p.? 17:7676381-7676381 15
9 COSM10905 TP53 salivary gland,major,carcinoma,NS c.451C>T p.P151S 17:7675161-7675161 15
10 COSM43951 TP53 salivary gland,major,carcinoma,NS c.643A>G p.S215G 17:7674888-7674888 15
11 COSM10659 TP53 salivary gland,major,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 15
12 COSM10705 TP53 salivary gland,major,carcinoma,NS c.586C>T p.R196* 17:7674945-7674945 15
13 COSM10648 TP53 salivary gland,major,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 15
14 COSM43931 TP53 salivary gland,major,carcinoma,NS c.523C>A p.R175S 17:7675089-7675089 15
15 COSM11354 TP53 salivary gland,major,carcinoma,NS c.991C>T p.Q331* 17:7673537-7673537 15
16 COSM43680 TP53 salivary gland,major,carcinoma,NS c.523C>T p.R175C 17:7675089-7675089 15
17 COSM44119 TP53 salivary gland,major,carcinoma,NS c.483C>T p.A161A 17:7675129-7675129 15
18 COSM10758 TP53 salivary gland,major,carcinoma,NS c.659A>G p.Y220C 17:7674872-7674872 15
19 COSM10786 TP53 salivary gland,major,carcinoma,NS c.949C>T p.Q317* 17:7673579-7673579 15
20 COSM10777 TP53 salivary gland,major,carcinoma,NS c.715A>G p.N239D 17:7674248-7674248 15
21 COSM6930930 TENT5C salivary gland,major,carcinoma,NS c.702G>C p.K234N 1:117623570-117623570 15
22 COSM6983859 TCF3 salivary gland,major,carcinoma,NS c.173C>T p.S58F 19:1632378-1632378 15
23 COSM6983856 SUZ12 salivary gland,major,carcinoma,NS c.766C>T p.R256C 17:31975656-31975656 15
24 COSM6951891 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 15
25 COSM6951889 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 15
26 COSM6939534 STAG2 salivary gland,major,carcinoma,NS c.2405T>G p.I802S 23:124071195-124071195 15
27 COSM6920823 STAG2 salivary gland,major,carcinoma,NS c.1808G>A p.G603E 23:124063192-124063192 15
28 COSM6924542 SPEN salivary gland,major,carcinoma,NS c.1648C>T p.R550C 1:15920882-15920882 15
29 COSM6939532 SOX9 salivary gland,major,carcinoma,NS c.1457T>A p.V486D 17:72124314-72124314 15
30 COSM6983831 SOX17 salivary gland,major,carcinoma,NS c.1181C>T p.A394V 8:54459931-54459931 15
31 COSM2769709 SMO salivary gland,major,carcinoma,NS c.1513C>T p.P505S 7:129210409-129210409 15
32 COSM6939526 SMO salivary gland,major,carcinoma,NS c.385G>C p.V129L 7:129203437-129203437 15
33 COSM1226761 SMARCA4 salivary gland,major,carcinoma,NS c.3967C>T p.R1323C 19:11034929-11034929 15
34 COSM6941870 SMARCA4 salivary gland,major,carcinoma,NS c.848C>G p.P283R 19:10986992-10986992 15
35 COSM6964890 SH2B3 salivary gland,major,carcinoma,NS c.241G>A p.D81N 12:111418386-111418386 15
36 COSM6951921 SH2B3 salivary gland,major,carcinoma,NS c.1226G>A p.G409E 12:111447534-111447534 15
37 COSM1159845 SF3B1 salivary gland,major,carcinoma,NS c.2324G>A p.R775Q 2:197401788-197401788 15
38 COSM5891771 SETD2 salivary gland,major,carcinoma,NS c.3994C>T p.P1332S 3:47084277-47084277 15
39 COSM5995773 SDHA salivary gland,major,carcinoma,NS c.724G>A p.G242R 5:228287-228287 15
40 COSM4991131 RPTOR salivary gland,major,carcinoma,NS c.3788C>T p.P1263L 17:80962556-80962556 15
41 COSM3451453 RPS6KA4 salivary gland,major,carcinoma,NS c.967C>T p.R323C 11:64365361-64365361 15
42 COSM6983822 ROS1 salivary gland,major,carcinoma,NS c.2878G>A p.G960R 6:117365676-117365676 15
43 COSM5610508 ROS1 salivary gland,major,carcinoma,NS c.5794G>A p.E1932K 6:117320014-117320014 15
44 COSM6983819 ROS1 salivary gland,major,carcinoma,NS c.5211A>T p.E1737D 6:117337209-117337209 15
45 COSM3726697 RNF43 salivary gland,major,carcinoma,NS c.434G>A p.R145Q 17:58363542-58363542 15
46 COSM6983815 RICTOR salivary gland,major,carcinoma,NS c.712C>T p.P238S 5:38981908-38981908 15
47 COSM1644939 RB1 salivary gland,major,carcinoma,NS c.1817A>G p.Y606C 13:48456206-48456206 15
48 COSM6913929 RASA1 salivary gland,major,carcinoma,NS c.2603+2T>A p.? 5:87379852-87379852 15
49 COSM6910894 RASA1 salivary gland,major,carcinoma,NS c.3026T>G p.L1009R 5:87389493-87389493 15
50 COSM6951920 RAD52 salivary gland,major,carcinoma,NS c.761C>G p.T254R 12:916448-916448 15
Sources

Expression for Salivary Gland Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Carcinoma.
Sources

Pathways for Salivary Gland Carcinoma

About this section

Pathways related to Salivary Gland Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Phospholipase-C Pathway 64
Show member pathways
 12.91 AREG EGFR HGF KIT MDM2 MET
2
Endometrial cancer 37
Show member pathways
 12.75 AREG CDKN2A EGFR KIT MDM2
3
Glioma 37
Show member pathways
 12.64 CDKN2A EGFR HGF MDM2 MET
4
MAPK signaling pathway 37 1
12.62 AREG EGFR HGF KIT MET
5
Gastric cancer 37
Show member pathways
 12.61 CDKN2A EGFR HGF KIT MET
6
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.55 EGFR HGF KIT MDM2 MET
7
Pathways in cancer 37
12.45 CDKN2A EGFR HGF KIT MDM2 MET
8
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.28 AREG EGFR HGF KIT MET
9
MicroRNAs in cancer 37
12.24 CDKN2A EGFR MDM2 MET TNN
10
Proteoglycans in cancer 37
12.1 EGFR HGF MDM2 MET
11
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.08 AREG EGFR HGF KIT MET
12
PI3K-Akt signaling pathway 37
Show member pathways
 12.07 AREG EGFR HGF KIT MAML2 MDM2
13
ErbB signaling pathway 1 37
Show member pathways
 12 AREG EGFR HGF MDM2 MET
14
Glioblastoma Multiforme 64
11.84 CDKN2A EGFR MDM2
15
Direct p53 effectors 1
11.83 EGFR HGF MDM2 MET
16
Listeria monocytogenes entry into host cells 66
Show member pathways
 11.73 EGFR HGF MET
17
Bladder cancer 37 1
11.62 CDKN2A EGFR MDM2
18
Central carbon metabolism in cancer 37
11.51 EGFR KIT MET
19
Signaling events mediated by TCPTP 1
Show member pathways
 11.26 EGFR HGF MET
20
Stabilization and expansion of the E-cadherin adherens junction 1
11.21 EGFR HGF MET
21
Arf6 signaling events 1
11.03 EGFR HGF MET
22
G-protein signaling_Rap2B regulation pathway 22
10.9 AREG EGFR HGF KIT MET
23
Syndecan-1-mediated signaling events 1
10.84 HGF MET
24
Extracellular vesicle-mediated signaling in recipient cells 1
10.61 EGFR HGF MET
Sources

GO Terms for Salivary Gland Carcinoma

About this section

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 AREG CDK9 CDKN2A CRTC1 CRTC3 CYLD
2 cell surface GO:0009986 9.35 AREG EGFR KIT MET TNN

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 EGFR HGF KIT MDM2 MET
2 positive regulation of cell proliferation GO:0008284 9.93 AREG EGFR ISL1 KIT MDM2
3 MAPK cascade GO:0000165 9.73 EGFR HGF KIT MET
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 EGFR KIT MET
5 cell proliferation GO:0008283 9.72 AREG CDK9 EGFR HGF MET
6 liver development GO:0001889 9.67 EGFR HGF MET
7 peptidyl-tyrosine phosphorylation GO:0018108 9.67 EGFR HGF KIT MET
8 endocardial cushion morphogenesis GO:0003203 9.58 ISL1 MDM2
9 positive regulation of CREB transcription factor activity GO:0032793 9.57 CRTC1 CRTC3
10 positive regulation of protein kinase B signaling GO:0051897 9.56 EGFR HGF KIT MET
11 hepatocyte growth factor receptor signaling pathway GO:0048012 9.52 HGF MET
12 tongue development GO:0043586 9.51 EGFR KIT
13 locomotor rhythm GO:0045475 9.48 MC3R MTA1
14 somatic stem cell division GO:0048103 9.46 CDKN2A KIT
15 amyloid fibril formation GO:1990000 9.4 CDKN2A MDM2
16 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 CDK9 CDKN2A CRTC1 CRTC3 EGFR HGF
17 phosphatidylinositol phosphorylation GO:0046854 9.26 EGFR HGF KIT MET
18 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 HGF MET

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.77 CDK9 EGFR KIT MET PNCK
2 protein tyrosine kinase activity GO:0004713 9.46 EGFR HGF KIT MET
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 EGFR KIT MET
4 cAMP response element binding protein binding GO:0008140 9.32 CRTC1 CRTC3
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 EGFR HGF KIT MET
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 EGFR HGF KIT MET
Sources

Sources for Salivary Gland Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....